Opus Genetics Inc expected to post a loss of 5 cents a share - Earnings Preview

Opus Genetics

04/03/2025 13:48

Opus Genetics Inc IRD.OQ IRD.O is expected to show a rise in quarterly revenue when it reports  results on March 6 (estimated) for the period ending December 31 2024

The Durham North Carolina-based  company is expected to report a 425.0% increase in revenue to $8.879 million from $1.69 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Opus Genetics Inc is for a loss of 5 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Opus Genetics Inc is $9.50​, above​ its last closing price of $0.97. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.25
-0.24
-0.29
Missed
-22.1
Jun. 30 2024
-0.28
-0.25
-0.30
Missed
-17.6
Mar. 31 2024
-0.11
-0.13
-0.29
Missed
-116.4​
Dec. 31 2023
-0.03
-0.05
-0.21
Missed
-300
​​Sep. 30 2023
-0.24
-0.22
0.25
Beat
212.6
Jun. 30 2023
-0.25
-0.23
-0.24
Missed
-6.2​
Mar. 31 2023
-0.18
-0.15
-0.28
Missed
-81.8
Dec. 31 2022
0.97
1.58
Beat
63.3

This summary was machine generated March 4 at 13:48 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)